RxDoctor Payments Data

Smriti Choudhary, MD

Internal Medicine · Webster, TXNPI 1619971553

Payments from drug & device makers

$2,950in general payments, 2019–2025

Across 162 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$425
  • Lilly USA, LLC$347
  • Amgen$337
  • AbbVie$313
  • AstraZeneca$191
  • Novartis$180
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,91999%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,950 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$338,592
Medicare patients
465
Services billed
5,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$101,584
EliquisApixaban65$75,146
JanuviaSitagliptin Phosphate64$72,775
JardianceEmpagliflozin36$59,529
XareltoRivaroxaban29$41,275
OrgovyxRelugolix11$30,535
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$25,991
Janumet XrSitagliptin Phos/Metformin Hcl18$25,392
Breo ElliptaFluticasone/Vilanterol36$23,623
MounjaroTirzepatide15$21,436
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,870
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$6,639
Atorvastatin Calcium592$6,481
Rosuvastatin Calcium174$4,730
Losartan Potassium226$3,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$425$101,58480 claims
PfizerEliquis$66$75,14665 claims
Boehringer IngelheimJardiance$76$59,52936 claims
GSKTrelegy Ellipta, Breo Ellipta$119$49,61466 claims
Johnson & JohnsonXarelto$81$41,27529 claims
Lilly USA, LLCMounjaro$347$21,43615 claims
AstraZenecaBreztri Aerosphere$191$9,87013 claims
AbbVieSynthroid$313$2,11445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →